Track topics on Twitter Track topics that are important to you
A Novo Nordisk drug candidate for type 2 diabetes beat Eli Lilly’s dulaglutide (Trulicity) in reducing blood sugar and body weight in patients studied in a late-stage clinical trial, the Denmark-based company says. The results could bring strong competition to one of Indianapolis-based Lilly’s top-selling products if Novo Nordisk’s experimental drug is approved by the […]
Original Article: Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head TestNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...